secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001453687-26-000081
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Q1 net loss $39.2M ($1.46/sh) vs $17.7M; cash $120.4M; pipeline advances
--------------------------------------------------------------------------------

- Net loss widened to $39.2M from $17.7M YoY; higher R&D spend on Phase 3 AURORA trial.
- Cash, equivalents & restricted cash $120.4M as of March 31; raised $14.6M via ATM in Q1.
- Phase 3 AURORA trial enrollment continues; Phase 2 TRITON in myositis initiated; HELIOS pediatric trial progress.
- R&D expenses $19.5M (up 33% YoY) due to AURORA; G&A $7.1M (down 14% YoY).
- Cash runway expected into mid-2027, supporting completion of Phase 3 AURORA trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368726000081/0001453687-26-000081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368726000081/rnac-20260430.htm
  HTML page:      https://secwatch.observer/filing/0001453687-26-000081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer